Sugi Predict
/ Targets
/ POLR1G
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to POLR1G by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection |
PHASE3 | UNKNOWN |
| Intracameral Antibiotic Safety Study |
PHASE3 | SUSPENDED |
| Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers |
PHASE1/PHASE2 | COMPLETED |
| Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) |
PHASE1/PHASE2 | RECRUITING |
| Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer |
PHASE2 | UNKNOWN |
| Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer |
PHASE2 | COMPLETED |
| Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma |
PHASE1/PHASE2 | COMPLETED |
| Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas |
PHASE1 | COMPLETED |
| A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors |
PHASE1 | COMPLETED |
| Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome |
PHASE1 | COMPLETED |
| A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors |
PHASE1 | COMPLETED |
| Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers |
PHASE1 | RECRUITING |
| AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers |
PHASE1 | COMPLETED |
| Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Spironolactone and XPB-1 Integrity in the TFIIH Complex |
nan | ENROLLING_BY_INVITATION |
| DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease |
nan | COMPLETED |
| Chromosomal Translocations in Chandigarh Police |
nan | COMPLETED |
| A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients |
nan | COMPLETED |
| Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics |
nan | UNKNOWN |
| Chronic Cough and CANVAS (Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome) |
nan | COMPLETED |
| Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission. |
nan | UNKNOWN |
| S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil |
nan | COMPLETED |
| Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581 |
nan | COMPLETED |
| DNA Repair Genes and Outcomes in Patients With Stage III NSCLC |
nan | UNKNOWN |
| Recombinant Interferon Alfa-2b in Treating Patients With Melanoma |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a POLR1G binder may also engage these)